Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

D.G. Cho



Author of

  • +

    P2.08 - Poster Session 2 - Radiotherapy (ID 198)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Radiation Oncology + Radiotherapy
    • Presentations: 1
    • +

      P2.08-015 - Stereotactic body radiotherapy with Helical tomotherapy for lung tumor: Treatment outcome and feasibility (ID 1758)

      09:30 - 09:30  |  Author(s): D.G. Cho

      • Abstract

      Background
      In this study we evaluated the feasibility and outcome of stereotactic body radiotherapy (SBRT) for lung tumors treated with helical tomotherapy.

      Methods
      Between December 2007 and January 2013, 26 Patients with a total of 49 lung tumors were treated with helical tomotherapy at a median 75 Gy of 10 fractions over 2 weeks. Thirteen lung lesions of primary lung tumors (group 1) and 36 of recurrent or metastatic lung tumors (group 2) were analyzed. Three patients received re-SBRT due to local recurrence after first SBRT were included. (Total 29 cases were analyzed). Radiation pneumonitis was graded according to the Common Terminology Criteria for Adverse Events V 4.0.

      Results
      The patients’ age was median 72 years (range, 47-82). Median follow up was 16 months (range, 2-57 months). Total 13 cases (45%) showed progressive disease after SBRT, and one of them was distant metastasis. Of 12 thoracic recurrences, in-field recurrences were noted in 5 patients and out-field recurrences in 7 patients. In group 1 (13 cases), there were 3 recurrences with 1 in-field thoracic recurrence, 1 out-field thoracic recurrence and 1 distant metastasis. Grade≥2 radiation pneumonitis was noted in 8 patients (30%). One patient died due to radiation pneumonitis at 2 months follow up after second SBRT.

      Conclusion
      The preliminary findings of our study suggest SBRT with helical tomotherapy is feasible for lung tumor treatment. But further studies with more patients and longer follow-up duration are required.

  • +

    P2.24 - Poster Session 2 - Supportive Care (ID 157)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Supportive Care
    • Presentations: 1
    • +

      P2.24-018 - Primary mediastinal Castleman' disease; Surgically curable anemia : A case report (ID 1268)

      09:30 - 09:30  |  Author(s): D.G. Cho

      • Abstract

      Background
      Castleman’s disease, an uncommon disease that causes benign lymph node hyperplasia, must be distinguished from reactive lymph node hyperplasia and malignancies. Unicentric Castleman’s disease in patients with anemia is rarely described.

      Methods
      We describe the case of a 25-year-old woman with plasma cell type of unicentric Castleman’s disease presenting as iron deficiency anemia. We report the clinical course from the initial presentation to diagnosis and surgical cure and review the literature.

      Results
      Figure 1 A 25-year-old woman was referred with abnormal chest X-ray which was found during pre-employment screening. She had no other complaints, and her previous medical history was unremarkable, as was her family medical history. No fever, acute infectious symptoms and signs, or any other abnormalities were found in the physical examination. Normocytic anemia was found based on initial blood tests (hemoglobin 7.7 g/dl, mean corpuscular volume 88.9 fl, with normal white blood cells, red blood cell distribution width, liver renal functions, and electrolytes). Further laboratory examinations (ferritin 89.0 ng/ml; serum iron 23 mg/dl; and total iron binding capacity 206 mg/dl) demonstrated that she was iron deficient. Chest X-ray and chest CT scan confirmed a mass (6x4x4 cm) at right superior and mid-mediastinum (Fig. 1). PET/CT showed paratracheal mass shows inhomogeneously high FDG uptake. In suspicion of lymphoma, diagnostic thoracoscopic surgery was planned. However, intraoperative frozen section diagnosis of a specimen was benign. Thus, the mass was completely removed and diagnosis was consistent with unicentric plasma cell type Castleman’s disease. Three months after surgery, without any medical intervention, the laboratory data had recovered to normal range (hemoglobin 14.5 g/dl). She receives regular follow ups and no recurrence has been found for 4 years since surgery.

      Conclusion
      The surgical resection would appear to be the optimal treatment modality, and constitutional symptoms may be resolved. The prognosis following complete surgical resection appears to be good.